Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer
Introduction: The effect of systemic administration of bevacizumab in cancer patients over a 5-year period after the beginning of chemotherapy treatment and comparison with a control group. Methods: The study population consists of adult patients with metastatic breast or colorectal cancer who had n...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-05-01
|
| Series: | Hellenic Journal of Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1109966616302366 |
| _version_ | 1819155372381831168 |
|---|---|
| author | Ioannis Kapelakis Konstantinos Toutouzas Maria Drakopoulou Archontoula Michelongona Flora Zagouri Aristotle Mpamias Paraskevi Pliatsika Meletios-Athanasios Dimopoulos Christodoulos Stefanadis Dimitrios Tousoulis |
| author_facet | Ioannis Kapelakis Konstantinos Toutouzas Maria Drakopoulou Archontoula Michelongona Flora Zagouri Aristotle Mpamias Paraskevi Pliatsika Meletios-Athanasios Dimopoulos Christodoulos Stefanadis Dimitrios Tousoulis |
| author_sort | Ioannis Kapelakis |
| collection | DOAJ |
| description | Introduction: The effect of systemic administration of bevacizumab in cancer patients over a 5-year period after the beginning of chemotherapy treatment and comparison with a control group.
Methods: The study population consists of adult patients with metastatic breast or colorectal cancer who had not previously received antineoplasmatic treatment. Patients were stratified into two groups according to treatment: one group was treated with conventional chemotherapy plus bevacizumab and the other group was treated with conventional chemotherapy alone. The two groups did not differ in their cardiovascular history or demographic characteristics.
Results: Fatal outcomes were more frequent in the bevacizumab group in total as well as in different periods of follow up. However, a statistically significant difference was noted at 12 months (P-value 0.007) for new deaths and at 24 (p-value 0.001) and 60 months (p-value 0.004) for all deaths. Moreover, patients who experienced a cardiovascular or thromboembolic event belonged exclusively to the bevacizumab group. At the 5-year follow-up, five patients in the bevacizumab group developed coronary artery disease (19.23%), four experienced an acute myocardial infarction (14.81%) and five patients suffered from a thromboembolic event (17.86%).
Conclusions: The addition of bevacizumab to conventional chemotherapy for metastatic breast or colorectal cancer increases the incidence of cardiovascular events, which is mainly due to the increased prevalence of myocardial infarction and thromboembolic events. |
| first_indexed | 2024-12-22T15:35:56Z |
| format | Article |
| id | doaj.art-73cbf9358fae4965850b94ddcedc581f |
| institution | Directory Open Access Journal |
| issn | 1109-9666 |
| language | English |
| last_indexed | 2024-12-22T15:35:56Z |
| publishDate | 2017-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hellenic Journal of Cardiology |
| spelling | doaj.art-73cbf9358fae4965850b94ddcedc581f2022-12-21T18:21:15ZengElsevierHellenic Journal of Cardiology1109-96662017-05-0158321521910.1016/j.hjc.2016.11.022Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancerIoannis Kapelakis0Konstantinos Toutouzas1Maria Drakopoulou2Archontoula Michelongona3Flora Zagouri4Aristotle Mpamias5Paraskevi Pliatsika6Meletios-Athanasios Dimopoulos7Christodoulos Stefanadis8Dimitrios Tousoulis9First Department of Cardiology, Athens Medical School, Athens, GreeceFirst Department of Cardiology, Athens Medical School, Athens, GreeceFirst Department of Cardiology, Athens Medical School, Athens, GreeceFirst Department of Cardiology, Athens Medical School, Athens, GreeceDepartment of Therapeutics, “Alexandra” Hospital, Athens Medical School, Athens, GreeceDepartment of Therapeutics, “Alexandra” Hospital, Athens Medical School, Athens, GreeceFirst Department of Cardiology, Athens Medical School, Athens, GreeceDepartment of Therapeutics, “Alexandra” Hospital, Athens Medical School, Athens, GreeceFirst Department of Cardiology, Athens Medical School, Athens, GreeceFirst Department of Cardiology, Athens Medical School, Athens, GreeceIntroduction: The effect of systemic administration of bevacizumab in cancer patients over a 5-year period after the beginning of chemotherapy treatment and comparison with a control group. Methods: The study population consists of adult patients with metastatic breast or colorectal cancer who had not previously received antineoplasmatic treatment. Patients were stratified into two groups according to treatment: one group was treated with conventional chemotherapy plus bevacizumab and the other group was treated with conventional chemotherapy alone. The two groups did not differ in their cardiovascular history or demographic characteristics. Results: Fatal outcomes were more frequent in the bevacizumab group in total as well as in different periods of follow up. However, a statistically significant difference was noted at 12 months (P-value 0.007) for new deaths and at 24 (p-value 0.001) and 60 months (p-value 0.004) for all deaths. Moreover, patients who experienced a cardiovascular or thromboembolic event belonged exclusively to the bevacizumab group. At the 5-year follow-up, five patients in the bevacizumab group developed coronary artery disease (19.23%), four experienced an acute myocardial infarction (14.81%) and five patients suffered from a thromboembolic event (17.86%). Conclusions: The addition of bevacizumab to conventional chemotherapy for metastatic breast or colorectal cancer increases the incidence of cardiovascular events, which is mainly due to the increased prevalence of myocardial infarction and thromboembolic events.http://www.sciencedirect.com/science/article/pii/S1109966616302366BevacizumabAngiogenesisCancerCoronary artery diseaseVascular endothelial growth factor |
| spellingShingle | Ioannis Kapelakis Konstantinos Toutouzas Maria Drakopoulou Archontoula Michelongona Flora Zagouri Aristotle Mpamias Paraskevi Pliatsika Meletios-Athanasios Dimopoulos Christodoulos Stefanadis Dimitrios Tousoulis Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer Hellenic Journal of Cardiology Bevacizumab Angiogenesis Cancer Coronary artery disease Vascular endothelial growth factor |
| title | Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer |
| title_full | Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer |
| title_fullStr | Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer |
| title_full_unstemmed | Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer |
| title_short | Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer |
| title_sort | bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer |
| topic | Bevacizumab Angiogenesis Cancer Coronary artery disease Vascular endothelial growth factor |
| url | http://www.sciencedirect.com/science/article/pii/S1109966616302366 |
| work_keys_str_mv | AT ioanniskapelakis bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT konstantinostoutouzas bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT mariadrakopoulou bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT archontoulamichelongona bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT florazagouri bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT aristotlempamias bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT paraskevipliatsika bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT meletiosathanasiosdimopoulos bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT christodoulosstefanadis bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer AT dimitriostousoulis bevacizumabincreasestheincidenceofcardiovasculareventsinpatientswithmetastaticbreastorcolorectalcancer |